Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology

By Y. Park, M. A. Tortorici, A. Walls, N. Czudnochowski, G. Snell, D. Veesler. 2020

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Alessandro Sette
2. Alba Grifoni
3. J. Dan
4. Shane Crotty
5. D. Weiskopf
6. J. Mateus
7. F. Krammer
8. M. McCallum

Citations in the corpus

• Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “…domain (RBD) in complex with ACE2 defined key residues involved in recognition and guide surveillance studies aiming to detect the emergence of mutants with altered binding affinity for ACE2 or distinct antigenicity (Lan et al., 2020; Shang et al., 2020; Wang et al., 2020b; Yan et al., 2020).”
• Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection (2021, background): “1, C and D), as RBD is the target of most neutralizing antibodies against SARS-CoV-2 (4, 27, 46, 47).”
• Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins (2021, result): “The Omicron S1 RBD structure showed high similarities with the 67 experimental structures (PDB: 6M17 and 6M0J) (Figure 1 D and E), and the comparison of 68 Omicron S1 RBD with experimental structures (PDB: 6M17[5], 6M0J [6], 6LZG [7], and 7JX3 69 [8]) showed low RMSD values (Figure 1F), which reflec”
• COVID-19 vaccines: where we stand and challenges ahead (2021, background): “The progressive elucidation of the critical role of this interaction provided the key insights that spurred several developers of innovative vaccine to target the Spike protein and its RBD [2, 66].”
• Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms (2020, methodology): “, an epitope that is fully contained within one S protomer; (ii) ~50% of S trimers naturally harbor one open RBD at the viral surface or in recombinantly expressed S ectodomain trimers as observed by cryo–electron tomography and singleparticle cryo-EM, respectively (6, 39); and (iii) S2E12 binding s”
• Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition (2020, unknown): “Our maps show that at a superficial level, the antibodies target just a few patches on the surface of the RBD that likely correspond to ‘‘antigenic regions’’ that have been defined using other approaches (Barnes et al., 2020b; Piccoli et al., 2020).”